# City Therapeutics Inc. (CTY) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $19.09, market value $961 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). City Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 70.8×**. Each dollar of revenue is priced at 70.8×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -4.6%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -441.8%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -431.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: 69.1%**. A 69.1% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 36.4%**. Return on all capital, debt included, is 36.4%: comfortably above what that capital costs.
- **Return on assets: -39.1%**. Each dollar of assets produces -39.1% of profit.

## Growth
- **Revenue growth (1 yr): 388.2%**. Revenue grew 388.2% over the last year.
- **EPS growth (1 yr): -142.1%**. Earnings per share fell 142.1%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: 0.8×**. It would take 0.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -26.5×**. Operating profit covers interest only -26.5×: fragile.
- **Current ratio: 3.07** (quick 3.07). Current assets cover the next year's liabilities 3.07 times.
- **Altman Z-score: 1.07**. A Z-score of 1.07 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. City Therapeutics Inc. does not currently pay a dividend.

## Price and momentum
- **From 52-week high: -20.1%** (1.7% above the low). Trading 20% below its 52-week high.

Live score and charts: https://foliofundamentals.com/analyzer?s=CTY · Page: https://foliofundamentals.com/stocks/cty

Not investment advice.